Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05578703 · ClinicalTrials.gov registry record · NA

ABLATE WEIGHT (Ablation Plus ESG for Weight Loss)

A NA study of Obesity, sponsored by True You Weight Loss.

Active
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT05578703: Active NA study of Obesity, sponsored by True You Weight Loss.

NCT05578703 is a NA study of Obesity that is active but no longer recruiting, run by True You Weight Loss. The registered enrollment target is 10 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05578703, a NA study of Obesity, is active but no longer recruiting, sponsored by True You Weight Loss.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to investigate the effects of fundic ablation (FA) on circulating plasma ghrelin, satiation, and total body weight loss, as well as the incidence of adverse events. This procedure will be carried out with the HybridAPC (ERBE Elektromedizin GmbH, Tübingen, Germany). The HybridAPC instrument creates an electric current to deliver a safe amount of thermal injury to a portion of the stomach known as the gastric fundus. This thermal injury will target a hormone called ghrelin which is the only known hormone linked to increasing appetite, calorie intake, and weight gain. This procedure is designed to target the bodily effects of appetite control and gastric sensory and motor functions which cause the feeling of fullness and satiation. The fundic mucosal ablation is not typically done prior to the endoscopic sleeve gastroplasty procedure. When fundic mucosal ablation is sequentially paired with endoscopic sleeve gastroplasty (ESG), this combined investigational approach may lead to decreased fasting ghrelin levels, improved satiation, and greater total body weight loss than traditional ESG. This study will help determine if the combined impact of FA with ESG should be made available to patients as part of a comprehensive weight loss strategy.

Conditions Studied

Interventions

  • PROCEDURE Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty
  • DEVICE Fundic Mucosal Ablation with ERBE HybridAPC
  • DEVICE Apollo ESG

Study Locations (1)

North Carolina

  • True You Weight Loss - Cary

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2022-11-09
Est. Completion 2026-06
Phase NA
True You Weight Loss

4 total trials

What the registry record for NCT05578703 still lists

NCT05578703 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty is the first listed.

NCT05578703 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT05578703 about?

NCT05578703 is a clinical study titled "ABLATE WEIGHT (Ablation Plus ESG for Weight Loss)". The purpose of this research is to investigate the effects of fundic ablation (FA) on circulating plasma ghrelin, satiation, and total body weight loss, as well as the incidence of adverse events. This procedure will be carried out with the HybridAPC (ERBE Elektromedizin GmbH, Tübingen, Germany). Th...

What is the current status of trial NCT05578703?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2022-11-09. Estimated completion is 2026-06.

What conditions does trial NCT05578703 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT05578703?

The interventions under investigation include: Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty (PROCEDURE), Fundic Mucosal Ablation with ERBE HybridAPC (DEVICE), Apollo ESG (DEVICE).

Who is sponsoring clinical trial NCT05578703?

This trial is sponsored by True You Weight Loss, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05578703 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05578703's enrollment target sits among peer trials

10 1025th of 1053 higher than 19 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05578703, the US trial registry maintained by the National Library of Medicine. NCT05578703 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.